Get the Stockscreener App
1.64
5.81%
0.09
After Hours:
1.63
-0.01
-0.61%
Okyo Pharma Limited stock is traded at $1.64, with a volume of 131.54K.
It is up +5.81% in the last 24 hours and up +5.81% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
131.54K
Relative Volume:
1.41
Market Cap:
$86.07M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-13.08
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
+19.71%
1M Performance:
+5.81%
6M Performance:
-23.00%
1Y Performance:
-40.36%
1-Day Range:
$1.485
$1.65
1-Week Range:
$1.38
$1.65
52-Week Range:
$1.3401
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.64 | 81.34M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma plans 111-patient Phase 3 corneal pain trial - Stock Titan
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO Pharma Ltd|Price:1.550|Chg%:+0.070 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
OKYO|OKYO Pharma Ltd|Price:1.550|Chg%:+0.070 - TradingKey
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase - Stock Titan
OKYO Pharma Director's Holding Reaches 35,201 Shares - Stock Titan
OKYO Pharma CEO purchases 15,000 shares at $1.54 each - Investing.com
OKYO Pharma CEO purchases 15,000 shares at $1.54 each By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares - Stock Titan
OKYO Pharma Plans Global Phase 3 Trial for About 111 Patients - Stock Titan
OKYO Pharma says CEO purchased 15,000 shares - Proactive financial news
OKYO Pharma director Brancaccio raises stake to 35,201 shares after $1.48 purchase - Bitget
OKYO Pharma executive purchases 3,500 shares at $1.40 each By Investing.com - Investing.com Australia
OKYO Pharma grants CMO 20,000 common shares | OKYO Insider Trading - Stock Titan
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial - TipRanks
OKYO Pharma Chairman buys 22,500 shares, raisin... - Pluang
OKYO Pharma (Nasdaq: OKYO) chair buys more shares, now owns 20.55% - Stock Titan
OKYO Pharma Announces Purchase of Shares by Chairman - GlobeNewswire
OKYO Pharma executive purchases 3,500 shares at $1.40 each - Investing.com India
OKYO Pharma CMO purchases 20,000 shares at $1.40 each By Investing.com - Investing.com South Africa
OKYO Pharma Chief Development Officer Gary S. Jacob Increases Shareholding with Open-Market Purchase - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director adds 3,500 shares at $1.40 - Stock Titan
OKYO Pharma director lifts holding to 112,420 shares - Stock Titan
OKYO Pharma announces chief medical officer share purchase - Proactive financial news
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial - TipRanks
OKYO Pharma CMO purchases 20,000 shares at $1.40 each - Investing.com
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CMO purchases 20,000 shares on market - Stock Titan
OKYO Pharma’s Chief Medical Officer Acquires 20,000 Shares at $1.40 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma Plans Phase 3 Trial for Single-Dose Eye Pain Drug - Stock Titan
OKYO Pharma CDO Jacob lifts stake to 112,420 shares with 3,500-share buy at $1.4 - Bitget
OKYO Pharma Ltd (OKYO) director awarded 25,000 shares of common stock - Stock Titan
OKYO Pharma chairman increases stake to 20.51% By Investing.com - Investing.com Nigeria
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):